BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 14728083)

  • 1. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
    Kane JM
    J Clin Psychiatry; 2003; 64 Suppl 19():3-5. PubMed ID: 14728083
    [No Abstract]   [Full Text] [Related]  

  • 2. Maintaining symptom control: review of ziprasidone long-term efficacy data.
    Schooler NR
    J Clin Psychiatry; 2003; 64 Suppl 19():26-32. PubMed ID: 14728087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability of ziprasidone: an expanding perspective.
    Daniel DG
    J Clin Psychiatry; 2003; 64 Suppl 19():40-9. PubMed ID: 14728089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
    Stahl SM; Shayegan DK
    J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziprasidone and cognition: the evolving story.
    Harvey PD
    J Clin Psychiatry; 2003; 64 Suppl 19():33-9. PubMed ID: 14728088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focus on ziprasidone.
    Green B
    Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ziprasidone (Geodon) for schizophrenia.
    Med Lett Drugs Ther; 2001 Jun; 43(1106):51-2. PubMed ID: 11402259
    [No Abstract]   [Full Text] [Related]  

  • 8. [Ziprasidone and dementia].
    Aakhus E
    Tidsskr Nor Laegeforen; 2004 Aug; 124(16):2155-6; author reply 2155-6. PubMed ID: 15334150
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone.
    Kuwilsky A; Krumm B; Englisch S; Dressing H; Zink M
    Pharmacopsychiatry; 2010 Aug; 43(6):216-20. PubMed ID: 20589598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Exercising caution in choice of psychotropic drugs. Avoid drug-induced weight gain].
    MMW Fortschr Med; 2002 May; Suppl 2():89. PubMed ID: 12070872
    [No Abstract]   [Full Text] [Related]  

  • 11. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.
    Brook S
    J Clin Psychiatry; 2003; 64 Suppl 19():13-8. PubMed ID: 14728085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for successful clinical management of schizophrenia with ziprasidone.
    Fagiolini A; Cañas F; Gallhofer B; Larmo I; Levy P; Montes JM; Papageorgiou G; Zink M; Rossi A
    Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials.
    Kane JM
    J Clin Psychiatry; 2003; 64 Suppl 19():19-25. PubMed ID: 14728086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care.
    Ritsner MS; Yorkov V; Ratner Y; Soifer P; Gibel A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1470-7. PubMed ID: 17669573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y; Gibel A; Yorkov V; Ritsner MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone: a novel psychotropic with unique properties.
    Ballas C; Yang C; O'Reardon J; Ballas P; Baldassano C
    Expert Rev Neurother; 2004 Mar; 4(2):179-86. PubMed ID: 15853558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.
    Rossi A; Cañas F; Fagiolini A; Larmo I; Levy P; Montes JM; Papageorgiou G; Sturlason R; Zink M; Correll CU
    Postgrad Med; 2011 Jan; 123(1):135-59. PubMed ID: 21293094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ziprasidone-associated pedal edema in the treatment of schizophrenia.
    Ku HL; Su TP; Chou YH
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):963-4. PubMed ID: 16624468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible ziprasidone-induced mania.
    Larson MF; Hauser A
    J Am Acad Child Adolesc Psychiatry; 2003 Sep; 42(9):1012; discussion 1012-3. PubMed ID: 12964565
    [No Abstract]   [Full Text] [Related]  

  • 20. From clinical research to clinical practice: a 4-year review of ziprasidone.
    Nemeroff CB; Lieberman JA; Weiden PJ; Harvey PD; Newcomer JW; Schatzberg AF; Kilts CD; Daniel DG
    CNS Spectr; 2005 Nov; 10(11 Suppl 17):1-20. PubMed ID: 16381088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.